OBJECTIVES: The efficacy of octreotide was studied in a group of patients with biochemical evidence of insulinoma. DESIGN: A phase-II study. SETTING: A university department of internal medicine. SUBJECTS: Seven patients with biochemical evidence of insulinoma and without metastatic lesions. INTERVENTION: Daily treatment with octreotide, a somatostatin analogue, mainly within the dosage of 100-300 micrograms day-1. The treatment was continued in patients with biochemical evidence of response or until surgery was undertaken. MAIN OUTCOME: Five patients avoided hypoglycaemic symptoms and had normalization of blood glucose values for a median of 15+ months (range 0.2-54 months). Two did not improve metabolically. The treatment was well tolerated and had no deleterious effects on blood glucose regulation. CONCLUSION: Octreotide seems to be a promising treatment for many of the patients with insulinoma who are not suitable for surgery.
OBJECTIVES: The efficacy of octreotide was studied in a group of patients with biochemical evidence of insulinoma. DESIGN: A phase-II study. SETTING: A university department of internal medicine. SUBJECTS: Seven patients with biochemical evidence of insulinoma and without metastatic lesions. INTERVENTION: Daily treatment with octreotide, a somatostatin analogue, mainly within the dosage of 100-300 micrograms day-1. The treatment was continued in patients with biochemical evidence of response or until surgery was undertaken. MAIN OUTCOME: Five patients avoided hypoglycaemic symptoms and had normalization of blood glucose values for a median of 15+ months (range 0.2-54 months). Two did not improve metabolically. The treatment was well tolerated and had no deleterious effects on blood glucose regulation. CONCLUSION:Octreotide seems to be a promising treatment for many of the patients with insulinoma who are not suitable for surgery.
Authors: Charles J Kim; Devon McKenzie; Joe K Joseph; Yasemin Aytaman; Milay Luis Lam; Lina Soni; Samy I McFarlane Journal: Am J Med Case Rep Date: 2019-06-18
Authors: Roberto Baldelli; A Barnabei; L Rizza; A M Isidori; F Rota; P Di Giacinto; A Paoloni; F Torino; S M Corsello; A Lenzi; M Appetecchia Journal: Front Endocrinol (Lausanne) Date: 2014-02-07 Impact factor: 5.555